4 research outputs found
Visiting and Narrating: An Interspecific Tale of Melancholia
My research uses sustainable book design as an outlet for studying the destructive dialogue between humans and the earth in the Anthropocene epoch. I investigate the effects of the Anthropocene on my own mental health, particularly attuned to moments of enlightenment and depression that arise as a result of the realities of human-made climate change. Our impact on earth has consequences that are both physical (droughts, flooding, illnesses/pandemics, etc.), and mental (stress, anxiety, depression, etc.). Exploring the phenomenon of loss of language in the depressed mind, I examine what experiences would improve this condition. This search leads me to the comfort I find in reading books and through the practice of finding myself in the written word. The acknowledgement of written language in books as both destructive (historically and culturally in Indigenous communities) and healing (as a sanctuary for independent mental and emotional growth) is the point of interest in this research.
Books exist as a vessel for communication, capturing historical shifts in societal values. In this way they serve as a dynamic timeline. Books move through space and thought, reflecting and dictating moments past, and also imagining futures. They are physically still and contained but breathe through their connection to other literary works ā fiction and nonfiction. This research will live similarly, communicating the present and future outcome of our time on earth as a result of our past; our actions, while fleeting, influence the reaction of the land. In my material explorations and compositions, I view the land as body and the body as text ā relational vessels for interspecific communication
Fludarabin, ciklofosfamid i rituksimab (FCR) u lijeÄenju bolesnika s kroniÄnom limfocitnom leukemijom (KLL): iskustvo KliniÄkoga bolniÄkog centra Zagreb [Fludarabine, cyclophosphamide and rituximab (FCR) in the treatment of chronic lymphocytic leukemia (CLL): University Hospital Centre Zagreb experience]
In clinical trials the combination of fludarabine, cyclophosphamide and rituximab (FCR) demonstrated superior results and became the gold standard for first-line treatment of fit patients with chronic lymphocytic leukemia (CLL). The aim of this study was to evaluate the efficacy, toxicity and feasibility of this protocol in everyday clinical practice. We Āretrospectively analyzed the outcomes of 43 CLL patients treated at the Division of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb. The dosing of rituximab differed from that in clinical trials, we administered 375mg/m2 of rituximab per cycle, in previously untreated patients for eight and in relapsed/refractory patients for six cycles. The response rate was 95% with 83% of complete remissions. Twentyānine patients received FCR as a frontāline therapy; three-year overall and progressionāfree survival were 90% and 80%, respectively. In relapsed/refractory disease threeāyear overall and progressionāfree survival were 86% and 62%, respectively. Severe neutropenias occurred in 46% and serious infections in 9% of patients. According to these results, the toxicity profile and treatment outcomes in everyday routine clinical practice are similar to those reported in clinical trials
FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): UNIVERSITY HOSPITAL CENTRE ZAGREB EXPERIENCE
U kliniÄkim je studijama kombinacija fludarabina, ciklofosfamida i rituksimaba (FCR) pokazala odliÄne rezultate u lijeÄenju bolesnika s kroniÄnom limfocitnom leukemijom (KLL) i postala zlatni standard u prvoj liniji lijeÄenja takvih bolesnika bez znatnijih komorbiditeta. Cilj rada bio je ispitati terapijsku djelotvornost, toksiÄnost i provedivost ovog protokola u svakodnevnoj kliniÄkoj praksi. Retrospektivno su analizirani tijek i ishodi lijeÄenja 43-oje bolesnika s KLL-om sa Zavoda za hematologiju Klinike za unutarnje bolesti KliniÄkoga bolniÄkog centra Zagreb. Shema primjene rituksimaba razlikovala se od one u kliniÄkim studijama; primjenjivan je infuzijski u dozi od 375 mg/m2 u svim ciklusima, u ukupno osam doza u prvoj, odnosno Å”est u kasnijim linijama lijeÄenja. Na lijeÄenje je odgovorilo 95% bolesnika, a 83% postignulo je kompletnu remisiju. TrogodiÅ”nje preživljenje i preživljenje bez progresije bolesti u prvoj liniji lijeÄenja (29 bolesnika) bilo je 90 i 80%, a u kasnijim linijama 86 i 62%. TeÅ”ke neutropenije zabilježene su u 46% bolesnika, a teÅ”ke infekcije u 9% bolesnika. Ishodi lijeÄenja i toksiÄni profil u svakodnevnome kliniÄkom radu usporedivi su s onima iz kliniÄkih studijaIn clinical trials the combination of fludarabine, cyclophosphamide and rituximab (FCR) demonstrated superior results and became the gold standard for first-line treatment of fit patients with chronic lymphocytic leukemia (CLL). The aim of this study was to evaluate the efficacy, toxicity and feasibility of this protocol in everyday clinical practice. We Āretrospectively analyzed the outcomes of 43 CLL patients treated at the Division of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb. The dosing of rituximab differed from that in clinical trials, we administered 375mg/m2 of rituximab per cycle, in previously untreated patients for eight and in relapsed/refractory patients for six cycles. The response rate was 95% with 83% of complete remissions. Twentyānine patients received FCR as a frontāline therapy; three-year overall and progressionāfree survival were 90% and 80%, respectively. In relapsed/refractory disease threeāyear overall and progressionāfree survival were 86% and 62%, respectively. Severe neutropenias occurred in 46% and serious infections in 9% of patients. According to these results, the toxicity profile and treatment outcomes in everyday routine clinical practice are similar to those reported in clinical trials